1 completed, 1 terminated. 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Frank C Sciurba: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Apixaban 2.5 MG, Apixaban 5MG, Aspirin - COVID-19 | Phase 3 | Terminated | Frank C Sciurba | 657 | 2020-09-07 | 2022-02-17 |
| Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD nasal delivery of heated and humidified air - COPD | Not applicable | Completed | Frank C Sciurba | 12 | 2019-07-15 | 2023-06-08 |
Bronchitis, Chronic (1) · COVID-19 (1) · Pulmonary Disease, Chronic Obstructive (1)
Aspirin (1) · Humidifiers (1) · apixaban (1)
United States (2)
Frank Sciurba (1)
PMID 34473343, PMID 34633405, PMID 37189091, PMID 37489818, PMID 37591523